jeu, Mai 23rd 2024
Galenica sees robust sales growth across all sectors, driven by strong pharmaceutical market.
Galenica experienced significant growth in the first four months of 2024, marking the first time the pharmacy group has reported sales figures for this period. Sales rose by 4.8% to CHF 1.26 billion between January and April, as announced on Thursday.
Both primary segments contributed to this growth. The Products & Care segment saw a 4.5% increase in sales to CHF 542.6 million, while the Logistics & IT segment grew by 5.6% to CHF 1.04 billion.
Compared to the same period in 2023, the first four months of 2024 had one additional sales day, which positively impacted sales growth by about 1%, according to the report. Additionally, the overall positive development of the Swiss pharmaceutical market, which grew by 4.0%, supported Galenica’s sales increase.
High additional sales of generics and biosimilars had a dampening effect on overall growth. This trend was driven by new measures promoting generics and biosimilars, including increased co-payment if patients choose more expensive original preparations.
Looking ahead, Galenica confirmed its positive outlook for 2024. The Group expects further growth, anticipating sales to increase between 3% and 5%. Operating profit (EBIT adj.) is projected to grow slightly faster, at 8% to 11%. The dividend is expected to be at least at the previous year’s level.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic